Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating
Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating
奧本海默將Seres治療公司的目標價從16美元調整為13美元，維持強於大盤的評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊